Chief Judge Sleet recently construed the terms of a pharmaceutical patent related to treatment of dysuria. In re: Alfuzosin Hydrochloride Patent Litigation, MDL Docket No. 08-md-1941-GMS, Order (D. Del. May 20, 2009). The following claim terms were construed:
– “effective dysuria controlling non-toxic amount of alfuzosine”
– “bladder neck disease”
– “neurological disorder”
– “benign hypertrophy of the prostate of alpha-adrenergic origin”
Specifically, the Court rejected certain proposed constructions where the party asked the Court to “import examples from the specification into the claims” as “contrary to Federal Circuit precedent.” Id.